ETF

L&G Pharma Breakthrough ETF

ISIN
IE00BF0H7608
Minimum investment
1 USD

How good is this fund, really?

See the rating in the app

About L&G Pharma Breakthrough ETF

Biotechnology firms that research, develop or manufacture orphan drugs worldwide are the holdings this Legal & General ETF is built around, via the Solactive Pharma Breakthrough Value Index Net Total Return. LGIM Managers (Europe) Limited runs it passively, buying index shares in index weights, and may use derivatives for efficient management. The fund carries a sustainable investment objective, meaning it favours companies that contribute to social goals, avoid significant harm and follow good governance. The US dollar class accumulates income. Its key information document sets a recommended holding period of 5 years and an ongoing charge of 0.49%.

Watch this fund for free Add L&G Pharma Breakthrough ETF to your watchlist in the PowerFunds app and we tell you when it falls behind the rest of its category.

Watch the fund for free

Where to buy L&G Pharma Breakthrough ETF — platforms and fees

Sold on 4 platforms we follow.

L&G Pharma Breakthrough ETF — its category

Sector Equity Biotechnology — PowerFunds rates 55 funds in this category every month.

Biotechnology funds →

Other funds